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Background: The age-dependent increase of chronic obstructive pulmonary disease (COPD) prevalence caused
by smoking and other inhalational exposures in the general population is well-known worldwide. However, time
trends are poorly known, due to lower number of high-quality studies especially following nationwide efforts on
diminishing exposure levels. This study aimed to compare the prevalence of COPD symptoms and their major
determinants in Finnish adults in 1996 and 2006.
Methods: Two identical postal surveys were conducted among two random population samples from Helsinki
using identical methodologies in 1996 and 2006, with 6,062 (76%) and 2,449 (62%) participants, respectively.
Results: The physician-diagnoses of COPD remained at 3.7%, whereas physician-diagnoses of asthma and use
of asthma medicines increased in both genders. Current smoking reduced from 33.4 to 27.3% (pB0.001), and
the amount of cigarettes smoked also reduced significantly. The crude prevalence of chronic productive cough
was 12.1 and 11.1%, wheezing with dyspnoea without a cold (wheezing triad) 7.3 and 7.7%, and dyspnoea
grade II 13.8 and 13.6%, in 1996 and 2006, respectively. Among subjects with physician-diagnosed COPD, the
prevalences of chronic productive cough and recurrent wheeze reduced significantly, from 60.6 to 40.7% and
53.5 to 38.5%, respectively.
Conclusion: From 1996 to 2006, the prevalence of obstructive airway symptoms common in different
phenotypes of COPD did not increase in Finnish adults. This suggests that the upward trend of COPD
prevalence might have reached a plateau. Current smoking and the quantities smoked diminished suggesting
a wider impact of stronger legislation and smoking-cessation efforts during the Finnish National Programme
for COPD.
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C
hronic obstructive pulmonary disease (COPD)
is globally a major public health problem and
one of the leading causes of morbidity, disability,
and death (1, 2). The most important cause of COPD
is smoking, but other inhalational exposures, genetic and
predisposition, and childhood infections have also been
implicated with a significant role in the development of
COPD (24). The disease is frequently unrecognised,
underdiagnosed, and undertreated, and is associated with
chronic symptoms that reduce the quality of life even
before the development of airflow limitation that lays the
foundation for current diagnostic criteria for COPD (3, 5).
Epidemiological studies using different diagnostic criteria
for chronic airflow limitation have reported increasing
prevalence estimates and future projections from various
countries (611), but interestingly some studies have also
shown stable (Finland and England) or even reducing
prevalences (Spain and the USA) (1215). COPD is
not an unidimensional disease, but instead encompasses
different phenotypes, shares common features, and coex-
ists with chronic asthma in adults (2, 16, 17). Diagnostic
criteria from the international guidelines advocate the use
of spirometry in confirming the diagnosis of not fully
reversible airways obstruction (18). These spirometric
criteria do not fully reflect the phenotypes of chronic
bronchitis, emphysema, and frequent exacerbators, and
the use of Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria in spirometry is debated
E U R O P E A N
C L I N I C A L  R E S P I R A T O R Y
J O U R N A L

European Clinical Respiratory Journal 2016. # 2016 Annette Kainu et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix,
transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
1
Citation: European Clinical Respiratory Journal 2016, 3: 31780 - http://dx.doi.org/10.3402/ecrj.v3.31780
(page number not for citation purpose)
(3, 1825). Thus, use of repeated and validated symptom-
based surveys is also valuable in the assessment of
prevalence COPD in a general population (3, 20). Com-
parisons of the prevalence figures between cohorts
are acceptable when published symptom patterns typical
for COPD are defined (26).
In the prevalence of asthma, a plateau has been
suggested (27), but despite growing evidence there is
less recognition for similar levelling off for COPD possibly
because varying diagnostic methods have made compar-
isons less conclusive (1215). From earlier studies, we
have shown that subjects with incident COPD were symp-
tomatic even 10 years prior to diagnosis, thus typical
respiratory symptoms could predict smokers potentially at
risk of developing COPD (28).
COPD is widely underdiagnosed, and thus, it is assumed
that estimates of its prevalence using physician-diagnoses
are significantly affected by the functionality of the
primary health care system (2832). Changes in smoking
habits and respiratory symptoms common in COPD
could be less dependent on the changes in health care
practices and diagnostic activity.
The aim of the present study was to compare the pre-
valence of physician-diagnosed COPD and related respira-
tory symptoms and their major determinants, smoking,
age, and sex, in Finnish adults in 1996 and 2006 to assess
time trends in prevalence.
Materials and methods
The FinEsS study is a joint Nordic study on clinical
respiratory epidemiology between Finland, Estonia, and
Sweden that began in 1996. The study protocol has been
reported earlier (33). In summary, both population
samples have been randomly selected from the national
population register stratified by sex and 10-year age
cohorts between 20 and 69 years using identical sampling
protocols selecting 8,000 subjects in Finland in 1996 and
4,000 subjects in 2006. Subjects that had died or moved
outside Helsinki before the questionnaire mailing were
excluded yielding a final sample of 7,990 and 3,968 subjects
in 1996 and 2006, respectively. In total, 6,062 subjects
(3,462 women) or 76% responded in 1996 and 2,449
subjects (1,365 women) or 62% responded in 2006. In the
2006 study, response rate fell especially in younger women
as reported earlier (33).
Ethics statement
The study protocol has been reviewed by the Ethics
Board of the Helsinki University Hospital.
Questionnaire and definitions
The FinEsS postal questionnaire was originally developed
for the first Swedish Obstructive Lung Disease in Northern
Sweden (OLIN) study in 1985 from a revised version of the
British Medical Research Council questionnaire (34, 35).
The study questionnaire has been published previously
(36). The postal questionnaires used were identical for the
first 15 questions. Only questions relevant to this paper are
outlined.
Chronic productive cough: Relates to affirmative answers
to three consecutive questions of ‘Do you usually have
phlegm when coughing, or do you have phlegm which is
difficult to bring up?’, ‘Do you bring up phlegm on most
days during periods of at least three successive months?’,
and ‘Have you had such periods during at least two
successive years?’.
Recurrent wheeze: ‘Have you had wheezing, whistling, or
a noisy sound in your chest when breathing?’
Wheeze 12 months: ‘Have you had wheezing or whistling
in the chest at any time in the last 12 months?’
Wheeze with dyspnoea: ‘Have you been at all breathless
when the wheezing sound was present?’
Wheeze without cold: ‘Did you have wheezing or whistling
when you didn’t have a cold?’
Wheeze triad: Positive answers all three questions of
wheeze 12 months, wheeze with dyspnoea and wheeze
without cold.
Dyspnoea grade II: ‘Do you get short of breath walking
with other people of your own age on level ground?’
Exercise provoking symptoms: ‘Do you usually have
breathlessness, wheeze, or severe cough on effort?’
Physician-diagnosis of asthma: ‘Have you been diagnosed
with asthma by a doctor?’
Physician-diagnosis of COPD: ‘Have you been diagnosed
with COPD, chronic bronchitis or emphysema by a
doctor?’
Use of asthma medicines: ‘Do you currently use asthma
medicines (permanently or as needed)?’
Self-reported allergic rhinoconjunctivitis (arc): ‘Have you
now or have you had any of the following diseases?
Allergic eye-/nose catarrh (hay fever)’
Symptoms suggestive of COPD refer to chronic produc-
tive cough, recurrent wheeze, wheeze triad, exercise
provoking symptoms, and dyspnoea grade II.
Current smoker refers to those currently or within 1 year
having been smoking any quantity of cigarettes, pipe, or
cigars. Former smokers are those who report previous
smoking, but who have quit smoking at least 1 year
previously. Ever smokers include all current and former
smokers, and non-smokers include only subjects who have
never smoked.
Statistical analyses
For prevalence comparisons, the two-sided chi-squared
test was used to analyse differences between groups,
and MantelHaenzel test was used for trends in age
and smoking categories. Prevalence analyses were stra-
tified for age, gender, and smoking history. For risk
analyses, multiple logistic regression was used to calcu
late odds ratios (OR) and 95% confidence intervals (CI).
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All statistical analyses were conducted using Statistical
Package for Social Sciences (IBM Corp. Released 2013.
IBM SPSS Statistics for Macintosh 22.0, Armonk, NY,
USA). P-values less than 0.05 were considered significant
in all analyses.
Results
Trends in prevalence 19962006
Physician-diagnosed COPD was reported in 3.7% of
responders both in 1996 and 2006 with a non-significant
gender difference (Table 1). The prevalence and frequency
of smoking decreased in both genders with the prevalence
of current smokers diminishing from 37.2 to 30.9% in men
(p0.001) and 29.7 to 22.7% in women (pB0.001). In
addition to a reduced proportion of responders reporting
current smoking, those smoking also reported smoking
smaller quantities of cigarettes with the largest reduction
in the group of 15 cigarettes/day in men from 18.7 to
12.7% in 1996 and 2006, respectively (pB0.001).
The crude prevalences of respiratory symptoms sugges-
tive of COPD remained unchanged, with only wheeze in
the last 12 months in women increasing significantly.
Chronic productive cough even decreased significantly in
women from 11.7% in 1996 to 9.6% in 2006. Dyspnoea
grade II and the wheeze triad remained unchanged during
10 years (Table 2). Symptoms suggestive of COPD, namely
chronic productive cough, wheeze triad, recurrent wheeze,
and dyspnoea grade II, show very little if any difference
between 1996 and 2006, when stratified by gender, age,
smoking history, and current smoking intensity (Table 2).
Almost all of the COPD-related symptoms remained
unchanged between 1996 and 2006 when age, gender, and
smoking history were taken into consideration (Fig. 1).
Chronic productive cough (OR 0.89; 95% CI 0.771.04),
wheeze triad (1.07; 0.901.29), and dyspnoea grade II
(OR 0.88; 0.761.01) did not show significant changes,
whereas more asthma-related symptoms of shortness of
breath in 12 months (OR 1.22; 1.071.40) and wheeze
during 12 months (OR 1.21; 1.081.37) increased slightly
during the 10-year interval.
COPD and chronic productive cough with previous
asthma
Of the subjects with physician-diagnosed COPD, 30.5 and
46.2% reported having a concurrent diagnosis of asthma
(p0.008) and 58.0 and 61.5% of allergic rhinoconjunc-
tivitis (p0.558), in 1996 and 2006, respectively. Use of
asthma medication was reported by 33.2% of subjects
with physician-diagnosed COPD in 1996, which had
increased up to 49.5% in the 2006 study responders
(p0.007). During the same time interval, the subjects
reporting physician-diagnosed asthma reported using
asthma medication from 71.1 to 70.3%. The prevalence
of COPD symptoms stratified by previous asthma shows
a slight inverse trend in COPD-related symptoms in
asthmatics. The overall prevalences of symptoms sugges-
tive of COPD in the population remained unchanged as
shown in Fig. 2. In 2006, symptoms were clearly more
prevalent in subjects with concurrent diagnosis of asthma
and slightly more prevalent in subjects with allergic rhino-
conjunctivitis. Allergic rhinoconjunctivitis and previous
asthma would seem to predispose towards more symptoms
also in smokers. However, among subjects with physician-
diagnosed COPD, the prevalences of chronic productive
cough and wheeze with dyspnoea reduced significantly from
60.6 to 40.7% (p0.001) and 50.0 to 37.4% (p0.019) in
1996 and 2006, respectively (Fig. 3). The decrease in chronic
productive cough was more pronounced among subjects
without concurrent self-reported asthma.
Risk factor analysis
In the multiple regression model using study year, sex, age,
smoking, and self-reported allergic rhinoconjunctivitis
as independent variables, chronic cough, and dyspnoea
grade II were significantly less prevalent, and the use
of asthma medication was significantly more prevalent
in 2006 compared to 1996. All symptoms suggestive of
Table 1. Prevalence (%) of respiratory symptoms and of
smoking in 1996 and 2006 by sex
Male Female All
1996
(%)
2006
(%)
1996
(%)
2006
(%)
1996
(%)
2006
(%)
Age
B40 years 44.7 39.1 46.0 38.9 45.4 39.0
4059 years 41.9 41.9 41.4 41.2 41.6 41.6
]60 years 13.4 19.0 12.6 19.9 13.0 19.5
Smoking
Non-smoker 39.9 42.9 54.9 55.2 48.4 49.7
Former smoker 22.8 26.3 15.5 22.1 18.6 24.0
Current smoker 37.2 30.9 29.7 22.7 32.9 26.3
Current smoking intensity (current smokers)
None 0.8 3.2 1.1 4.0 0.9 3.6
B5 cigarettes/day 18.1 27.7 24.0 25.1 21.1 26.5
514 cigarettes/day 34.1 31.2 43.9 42.2 39.1 36.6
]15 cigarettes/day 46.9 37.9 31.1 28.5 38.8 33.3
Use of asthma
medication
4.6 7.7 7.0 10.7 6.0 9.4
Previous asthma 6.1 9.7 8.0 11.3 7.2 10.6
Allergic
rhinoconjunctivitis
32.8 38.7 39.9 45.9 36.9 42.7
Physician-diagnosis of
asthma
5.6 9.3 7.3 10.6 6.6 10.0
Physician-diagnosis of
COPD
4.1 3.5 3.5 3.9 3.7 3.7
Statistical significance pB0.05 is indicated by bold font.
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COPD increased with age, reported current smoking, and
the presence of allergic rhinoconjuncitivitis (Table 3).
Discussion
This large general population-based repeated postal
survey study found no further increase after 1996 in
symptoms suggestive of COPD among Finnish adult
residents in the Helsinki capital area. From 1996 to
2006, the study responders reported no increase in
physician-diagnoses of COPD. However, it is known
that considerable underdiagnosis and underrecognition
occurs with COPD; and thus, we analysed the trends
in prevalences of symptoms suggestive of COPD and
found no increase in COPD-related symptoms in the
general population. Among subjects with physician-diag-
nosed COPD, the prevalence of symptoms even slightly
decreased. This study reinforces the finding that COPD
prevalence has indeed reached a plateau with symptoms
suggestive of COPD showing no significant changes in
either gender.
Table 2. Prevalence (%) of chronic productive cough, recurrent wheeze, wheeze triad, and dyspnoea grade II stratified by age,
sex, and smoking history, in 1996 and 2006, respectively
Chronic productive cough Recurrent wheeze Wheeze triad Dyspnoea grade II
1996
(%)
2006
(%) P
1996
(%)
2006
(%) P
1996
(%)
2006
(%) P
1996
(%)
2006
(%) P
All 12.1 11.1 0.188 7.3 7.2 0.914 7.3 7.7 0.535 13.8 13.6 0.726
Sex
Female 11.7 9.6 0.036 6.5 6.7 0.832 7.4 7.6 0.763 16.3 15.1 0.294
Male 12.7 13.0 0.794 8.3 7.9 0.672 7.3 7.8 0.551 10.5 11.6 0.339
Age
B40 years 9.1 8.7 0.692 5.3 5.1 0.804 6.5 9.0 0.010 7.3 5.9 0.123
4059.9 years 13.0 11.3 0.165 8.1 7.9 0.792 7.5 7.2 0.742 16.5 15.1 0.305
]60 years 19.8 15.5 0.053 11.5 10.1 0.444 9.7 6.3 0.036 28.0 25.6 0.349
Smoking
Non-smoker 8.0 6.9 0.223 3.9 3.4 0.504 4.9 5.6 0.340 10.4 8.6 0.083
Former smoker 11.9 11.1 0.625 7.1 7.3 0.855 8.0 8.0 0.980 17.4 18.6 0.534
Current smoker 18.3 19.1 0.677 12.4 14.3 0.225 10.6 11.5 0.521 16.9 18.3 0.427
Current smoking intensity
None 9.2 7.9 0.119 4.6 4.1 0.337 5.7 6.0 0.668 12.1 11.6 0.599
B5 cigarettes/day 7.3 9.0 0.457 4.3 8.5 0.030 5.8 11.5 0.011 9.2 8.5 0.758
514 cigarettes/day 13.6 15.0 0.564 10.3 10.5 0.932 9.5 10.1 0.751 14.9 18.0 0.230
]15 cigarettes/day 27.4 31.8 0.182 18.6 25.5 0.018 13.6 14.2 0.814 23.8 27.2 0.277
0
0,2
0,4
0,6
0,8
1
1,2
1,4
chronic productive
cough
recurrent wheeze wheeze triad excercise provoking
symptoms
dyspnea grade II
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Fig. 1. Adjusted odds ratios of study year 2006 versus 1996 for prevalence of symptoms suggestive of COPD. Multiple logistic
regression analysis was performed with adjustment for age, sex, and smoking history (non, former, and current). Ninety-five
percent confidence intervals are included.
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Trends in symptoms of COPD
The prevalence of COPD symptoms on average did not
change during the 10 years in the general population.
Chronic productive cough diminished in women, but this
was related to less prevalent current smoking and after
taking current smoking into account on a multivariate
model, there were no significant changes. Previously,
it has been suggested that females would be more likely
to report breathlessness and cough, whereas males would
be more likely to report phlegm (37). Our findings are
consistent with these results showing lower reported
prevalences of chronic productive cough and higher
prevalences of dyspnoea grade II in women both in
1996 and 2006 with the prevalence of chronic productive
cough decreasing significantly from 11.7 to 9.6%
(p0.036). Symptoms related to wheeze were on com-
12,1%
11,1%
7,3% 7,2% 7,3%
7,7%
13,8% 13,6%
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Fig. 2. Prevalence (%) of respiratory symptoms suggestive of COPD in 1996 and 2006 in the Finnish general population.
0% 10% 20% 30% 40% 50% 60% 70% 80%
dyspnea grade II
excercise provoking
symptoms
wheeze triad
recurrent wheeze
chronic product ve cough
Prevalence (%) of symptom
1996 (n=226) 2006 (n=91)
1996 never asthma (n=150) 2006 never asthma (n=50)
p=0.001
p<0.001
p=0.015
Fig. 3. Prevalence (%) of respiratory symptoms suggestive of COPD in subjects with physician-diagnosed chronic obstructive
pulmonary disease (COPD) in the general Finnish population in the 1996 and 2006 surveys stratified by previous history of
asthma.
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parable levels in both genders. In the Mini-Finland Study
from 1978 to 1980, chronic bronchitis was reported in
23.8 and 13.8% and dyspnoea grade II in 10.1 and 12.8%
of men and women, respectively (38). In that study, half
of the women reporting chronic bronchitis were lifelong
never smokers. Also Lundba¨ck et al. have previously
reported higher prevalence of chronic productive cough
in never smoking women; and it has been hypothetised
that women are more susceptible to smoking-related
adverse effects on lung function and chronic bronchitis
(3941). In our study 38.2% of women and 24.1% of
men reporting chronic productive cough in 2006 were
non-smokers, the proportion of non-smokers did not
change from 1996. The impacts of environmental tobacco
exposure (ETS) and unrecognised asthma on the higher
prevalences of chronic bronchitis in non-smoking women
have not been fully evaluated. ETS has been shown
to increase bronchial hyperreactivity (42). In both our
surveys, chronic productive cough was assessed with
exactly same format of questions in 1996 and 2006 as
in the Mini Finland Study and showing a consisten-
tly reducing trend. Concurrently, implemented tobacco-
control measures have reduced ETS exposure, and
besides a true increase in asthma prevalence, the improved
recognition of asthma in primary care has increased the
proportion of diagnosed asthmatics from 1.4% in men
and 2.2% in women during the Mini Finland Study to 9.3
and 10.6% in men and women, respectively, in our 2006
survey (39).
In Northern Finland, a similar survey was conducted in
1996, where chronic productive cough was found in 11.5%
and dyspnoea grade II in 14.6% (43). The prevalence of
smoking and ETS in Kemi was slightly higher. In 1996,
chronic productive cough was reported in 5.6% in Stock-
holm, 11.7% in Helsinki, and 8.9% in Tallinn, whereas
both long-standing cough and sputum production were
more prevalent in Tallinn in line with more prevalent
smoking in Estonia at the time (26). No prospective data
are available from the other capitals to assess possible
concurrent trends in prevalence at this stage.
Limited data exist of longitudinal evaluation of COPD
symptoms in the general population, since most studies
have followed cohorts of COPD patients over time (8, 44).
In a longitudinal study on symptoms in a COPD cohort,
the symptom reporting was similar by sex over 3 years
(45). In severe COPD, symptoms may vary greatly over
the day and the week, with breathlessness being the most
common symptom (46). Dyspnoea has been found to be
the most disabling symptom of COPD correlating more
closely with health-related quality of life and decreased
activity levels (47). In our study, the crude prevalence of
dyspnoea grade II remained unchanged in both genders.
Undiagnosed COPD has been found to be associated
with impaired health-related quality of life and activities
of daily living. Symptoms are already more prevalentT
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several years previously in subjects with incident COPD
(5, 28, 44). The observed plateau in symptoms related
to COPD would suggest that the true trend of prevalence
of symptomatic COPD might remain at a steady state
with no evidence to support the increases in COPD
prevalence, morbidity, and mortality projected in other
countries (1, 9, 11).
Questionnaire data on screening and case finding of
COPD
Several studies have evaluated the role of questionnaires in
assessing the prevalence and detection of COPD. Barr
et al. validated the self-reported COPD in a cohort of
nurses and confirmed from medical records 78% of cases
reporting a physician-diagnosis of COPD. It was suggested
that questionnaire-based COPD research should focus on
minimising false positives rather than false negatives (48).
In general, true cases of COPD are often symptomatic if
detailed questions of respiratory symptoms are evaluated,
whereas subjects might not actively observe these symp-
toms or might relate them to continued smoking. From
the Lung Function Questionnaire (LFQ), symptoms of
wheeze, dyspnoea, and cough in addition to age and
smoking, predicted best airflow obstruction consistent
with COPD in the population (49). In another study,
an overall LFQ score of 18 or less was found to have a
relatively good sensitivity of 88%, but weaker specificity
of 25%, thus showing potential for being used for screen-
ing subjects for further spirometry. Questionnaire data
alone had a low positive predictive value but good negative
predictive value (50).
Trends in smoking
This repeated cross-sectional survey shows a declining
trend both in current smoking and in the smoking
intensity in both genders. The timing of our study relates
to a nationwide change in anti-smoking legislation, which
has further banned smoking in workplaces (from 1995)
and restaurants (from 2003 to 2007) (51). The Finnish
National COPD Programme from 1998 to 2007 also
included efforts in provision of smoking cessation services
and knowledge to the primary care (52). Concurrently
new pharmaceutical products came into market providing
new tools and also public interest in smoking cessation
efforts. These might have contributed to the observed
significant reduction in smoking prevalences. Despite
the observed decrease in prevalence of smoking in women
between 1996 and 2006, current smoking remained
still higher than in the Mini Finland Study from 1978 to
1980. The prevalence of current smoking continued on
a decreasing trend compared to both our 1996 survey
and the results from the nationwide Health 2000 study
(12, 38).
Trends in physician-diagnoses of asthma and COPD
The physician-diagnoses of asthma increased during the
observed time interval, which has been hypothetised to
relate to better recognition of asthma in the primary care
following the Finnish Asthma Programme 19942004
(33, 53). In the Mini Finland Health Survey, 1.4% men
and 2.2% women reported previously diagnosed asthma,
whereas 2.8% of men and 5.2% women had previous
asthma in the Health 2000 survey (12, 38). In our study,
the prevalence of self-reported physician-diagnosed asth-
ma increased from 5.6 to 9.3% in men and 7.3 to 10.6%
in women between the 1996 and 2006 surveys. It has
also been reported that the diagnosed asthmatics were
less symptomatic suggesting better asthma-control in the
diagnosed subjects (33). However, physician-diagnoses
of COPD remained unchanged during the same time
period. It has been questioned whether or not this would
be related to lack of recognition of COPD or possibly
diagnostic mislabelling of COPD as asthma. The latter
cannot be excluded by questionnaire data, but our results
show that symptoms suggestive of symptomatic COPD in
the population did not increase but instead key symptoms
of chronic productive cough and dyspnoea grade II even
decreased, when the confounding variables of gender, age,
smoking history, and allergic rhinoconjunctivitis were
taken into consideration (Table 3). The question of
physician-diagnosed COPD includes chronic bronchitis,
which is a symptom-based diagnosis, making our defini-
tion of physician-diagnosed COPD broader than strictly
obstruction-based diagnosis of COPD. Current smoking
continued to show a decreasing trend with both the
number of subjects reporting to have smoked during the
preceding 12 months and the amount currently smoked
per day decreasing significantly both in men and women
and in all age categories.
Globally rising trends of prevalences of obstruction
and COPD have been reported and further increases
projected (13, 69, 11, 32, 54). The diagnostic criteria
used in lung function measurements result in caution
comparing the results. Assessment of COPD prevalence
using repeated cross-sectional studies with spirometry can
also have biases with an unexpectedly large reduction
in COPD prevalence observed in Spain, demonstrating
also a wide difference in prevalence estimates depending
on the criteria used (14). These difficulties of assessing
COPD prevalence in cross-sectional studies raise the im-
portant issue of caution when making deductions from
single studies evaluating the prevalence of complex
disorders like COPD (14). Our findings are consistent
with previously reported lung function data from the
Health 2000 study in Finland and further reinforce the
observation of a plateau in the prevalence of sympto-
matic COPD in Finland. These findings also provide
further support to the continuing efforts of anti-tobacco
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measures and improved identification and active treat-
ment of both asthma and COPD in the primary care.
Strengths and limitations
The present study applied similar postal questionnaire
surveys in 1996 and 2006 using identical sampling. The
response rate in 2006 decreased especially in young female
adults (33). COPD, however, is known to be a disease most
prevalent in the older age cohorts and strongly associated
with a prior history of smoking; thus, the decreasing
response rate in young women could impact as a slight
overestimation of COPD symptoms, thus strengthening
our results of no increase in COPD-related symptoms.
Another limitation is the format of the questionnaire
survey, with no clinical data to verify the diagnoses of
COPD or asthma. In the US, self-reported COPD could
be confirmed by clinical data on medical records in 78%
of the self-reported diagnoses in a study on nurses (48).
From a nationally representative sample of the Health
2000 study, no change in the prevalence of airflow limi-
tation consistent with COPD has been reported compared
to the 19781980 Mini Finland study (12). Respiratory
symptoms or concurrent diagnoses of asthma or allergic
rhinoconjunctivitis were not assessed from that sample.
The strengths of our study rise from using strictly con-
trolled survey sampling and validated questionnaire meth-
odology in two cohorts 10 years apart. The subjects were
surveyed using their regular medication; thus, asthmatic
subjects were evaluated during their regular treatment.
Conclusion
In conclusion, the present study demonstrated that
symptoms of COPD and chronic bronchitis have not
increased in prevalence from 1996 to 2006 in Finnish
adults. The observed decrease in current smoking and
the amounts smoked may contribute to this finding in
addition to improved recognition of asthma in primary
care. This gives further support to the continuing efforts to
target the recognised risk factors for COPD to eventually
turn the tide in COPD prevalence and the rising health
care and human costs related to this chronic condition.
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